Novo Nordisk Shares Face Steep Decline Amid Strategic Shifts

The Danish pharmaceutical powerhouse, once celebrated for its groundbreaking weight-loss treatment Wegovy, is confronting a severe market downturn. A combination of disappointing quarterly results, a sweeping boardroom overhaul, and a failed multi-billion dollar acquisition has significantly rattled investor confidence. As competitor Eli Lilly extends its lead in the key U.S. market, critical questions emerge regarding Novo Nordisk’s capacity to navigate this challenging period and reclaim its competitive standing.

In a dramatic response to mounting pressures, the company’s principal shareholder has initiated a comprehensive restructuring of its supervisory board. The Novo Nordisk Foundation, controlling 75% of voting rights, orchestrated an extraordinary general meeting that resulted in the replacement of nearly Read more...